Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06825260 · ClinicalTrials.gov registry record · Phase 4
PEG3350 vs Senna After Urogyn Surgery
A Phase 4 study of Obstructive Defecation Syndrome and Postoperative Constipation, sponsored by St. Joseph's Health, New York.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 254
- Enrollment target
- 1
- Study location
NCT06825260: Recruiting Phase 4 study of Obstructive Defecation Syndrome and Postoperative Constipation, sponsored by St. Joseph's Health, New York.
NCT06825260 is a Phase 4 study of Obstructive Defecation Syndrome and Postoperative Constipation that is actively recruiting participants, run by St. Joseph's Health, New York. The registered enrollment target is 254 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06825260, a Phase 4 study of Obstructive Defecation Syndrome and Postoperative Constipation, is actively recruiting participants, sponsored by St. Joseph's Health, New York.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 254 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to evaluate whether polyethylene glycol 3350 (PEG3350) versus senna is better at relieving postoperative constipation after urogynecologic surgery. The main questions it aims to answer are: What number of patients taking PEG3350 have obstructed defecation syndrome (ODS), a form of constipation, vs those taking senna in the week after urogynecologic surgery? What patient-level and procedure-level characteristics are associated with postoperative ODS, in patients taking PEG3350 vs senna? participants will: Take their randomized medication daily for seven days after surgery Fill out an ODS questionnaire before and one week after surgery Complete a daily bowel diary for 7 days after surgery
Primary Outcome
The primary outcome is to determine the proportion of patients with postoperative obstructed defecation syndrome (ODS), defined as a score of nine or greater on the ODS questionnaire, in patients taking PEG3350 vs senna in the week after urogynecologic surgery.
Conditions Studied
Interventions
- DRUG Senna
- DRUG Polyethylene glycol 3350
Study Locations (1)
New York
- St. Joseph's Health Hospital - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2025-04-23 |
| Est. Completion | 2027-07 |
| Phase | Phase 4 |
What NCT06825260 shows while recruiting
NCT06825260 is an interventional study that assigns participants to a tested intervention. The registered 254 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (51% lower).
The record links to 2 conditions, with Obstructive Defecation Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Senna is the first listed.
NCT06825260 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06825260 about?
NCT06825260 is a clinical study titled "PEG3350 vs Senna After Urogyn Surgery". The goal of this study is to evaluate whether polyethylene glycol 3350 (PEG3350) versus senna is better at relieving postoperative constipation after urogynecologic surgery. The main questions it aims to answer are: What number of patients taking PEG3350 have obstructed defecation syndrome (ODS), a...
What is the current status of trial NCT06825260?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 254 participants. The study started on 2025-04-23. Estimated completion is 2027-07.
What conditions does trial NCT06825260 study?
This clinical trial studies the following conditions: Obstructive Defecation Syndrome, Postoperative Constipation.
What interventions are being tested in trial NCT06825260?
The interventions under investigation include: Senna (DRUG), Polyethylene glycol 3350 (DRUG).
Who is sponsoring clinical trial NCT06825260?
This trial is sponsored by St. Joseph's Health, New York, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06825260 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06825260's enrollment target sits among peer trials
254 337th of 2000 higher than 1,663 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI